Andros Pharmaceuticals held its annual shareholders' meeting yesterday (June 25), where it approved last year's business report, financial statements, and loss compensation proposal. The meeting also passed resolutions for private placement of common shares, issuance of restricted employee shares, and the addition of a new independent director, Professor Hsiao Hung-yi from Soochow University's School of Law. Looking ahead to this year, Andros stated that its operational focus will be on completing Phase II clinical trials for two new drugs: APC101 analgesic spray (head and neck) and APC201 anti-inflammatory and analgesic foam. The company maintains a positive outlook on its overall operations.
Andros' shareholders' meeting was chaired by Chairwoman Ai-Chun Wang. She explained that while the company's new drug products are still in clinical trial stages and generic drug sales have not yet reached economies of scale, resulting in a lack of profitability, last year's clinical trial progress followed plans and reached milestone achievements. The company also completed its listing on the Emerging Stock Board. This year, Andros will accelerate various clinical trial processes and promote niche generic drugs while actively negotiating technology transfer opportunities.
Wang stated that this year's operational focus will be on completing Phase II clinical trials for two new drugs: APC101 analgesic spray (head and neck) and APC201 anti-inflammatory and analgesic foam. Simultaneously, the company will apply for Phase III clinical trials of APC101 (systemic use). Additionally, two niche generic drugs are undergoing regulatory review in China and Taiwan, with hopes of obtaining approval this year.
Wang further noted that the Phase II clinical trial for APC101 in treating postherpetic neuralgia in the head and neck area has been approved by the TFDA and will enroll 21 patients Androsss two medical centers in Taiwan. Upon completion of Phase II, the company will seek orphan drug designation and fast-track approval in the U.S. to accelerate Phase III trials. Concurrently, Andros will apply for Phase III clinical trials of APC101 for systemic postherpetic neuralgia, enhancing product value and technology licensing opportunities.
The Phase I clinical trial for APC201 in treating osteoarthritis pain was completed late last year. Phase II trials are currently underway at three clinical trial centers in Australia, aiming to recruit 60 patients. The goal is to complete the Phase II efficacy trial this year and plan for Phase III clinical trials.
Regarding niche generic drugs, the LPC cream, previously licensed to a Hong Kong partner, completed its bioequivalence study last year and has been submitted to China's National Medical Products Administration (NMPA) for marketing authorization. Additionally, the company's self-developed local anesthetic compound cream, LTC cream (lidocaine/tetracaine cream), is currently under regulatory review in Taiwan. This product's main feature is its ability to form a soft film on the skin surface after application, releasing the drug into the skin for faster onset. As there are currently no generic products with the same composition in Taiwan, Andros has the opportunity to secure the first generic drug approval.
Looking ahead, Wang stated that Andros' operational strategy remains focused on developing new formulation drugs, complemented by niche generic drug development. The production and sales of niche generic drugs will help improve production line utilization and generate operating cash flow. This year, the company will actively expand its distribution partnerships and strengthen sales capabilities to boost revenue. Simultaneously, Andros aims to advance its new drug products to Phase III clinical trials, enhancing their licensing value. The company maintains a positive outlook on its overall operations.
Resource (mandarin)
